AstraZeneca beefs-up cancer portfolio in all-cash $2 billion acquisition
$2 billion cash acquisition beefs-up cancer portfolioFusion has prostate cancer drug in mid-stage trialsCash consideration pitched at 126% premiumPharmaceutical giant AstraZeneca (AZN) has agreed to buy Nasdaq-listed Fusion...
19 March 2024